Cyclopharm Limited · ASX:CYC
Cyclopharm — Investor Presentation (September 2023)
22 slides from Cyclopharm's investor presentation, Sep 26, 2023
Slide 1: Cyclopharm Investor Update
For personal use only CYCLOPHARM Investor Update 26 September 2023 1
Slide 2: Safe Harbour Statement
Certain views expressed here contain information derived from publicly available sources that have not been independently verified. The presentation includes certain statements, estimates and projections with respect For personal use only to the anticipated future financial performance of Cyclopharm
Slide 3: Technegas Around the World
TECHNEGAS® AROUND THE WORLD For personal use only Technegas® was introduced Technegas® revenues are generated in Over 4.7 million to the medical community 64 countries via a combination patient procedures in 1986 of direct and distributor sales models to date 3
Slide 4: For personal use only
4 For personal use only
Slide 5: A World Leading Diagnostic Imaging Company
A World Leading Diagnostic Imaging Company Recovery in FY 2022 continued from initial COVID-19 impact in primary country markets with 1 record sales of $23.2m. (Technegas sales $13.66m up 4.1% - Third-party sales $9.22 up 124% compared to 2021) For personal use only Continued underlying profitabilit
Slide 6: Financial & Operational Highlights
FY 2022: $22.88 million - a pcp increase of 32% Sales Revenue H1 2023: 14.92 million – a pcp increase of 35% For personal use only Third Party Distribution FY 2022: $9.22 million of 3rd party distribution revenue, more than double of FY21 H1 2023: $7.27 million of 3rd party distribution revenue Net
Slide 7: Third Party Distribution
THIRD PARTY DISTRIBUTION A Unique Asset Built Over the Past Six Years – 8 Offices Directly Servicing 18 of 64 Existing Markets Cyclopharm has established a respected global distribution and service network for nuclear medicine and For personal use only 1 molecular imaging products Other industry man
Slide 8: Counting Down to USA Launch
For personal use only Counting Down to USA Launch 8
Slide 9: Immediate Pulmonary Embolism Market Opportunity
600K Nuclear Medicine Ventilation 15%/600k Procedures p.a. • The Company estimates 4,000,000 patient procedures are conducted in For personal use only the USA per annum to diagnose pulmonary embolism (15% Nuclear Medicine – 85% CTPA) • ~600,000 Nuclear Medicine Ventilation pre-COVID procedures equal
Slide 10: USA Customer Demand Established
USA Customer Demand Established The Wait Is Nearly Over Technegas generator placement strategy targeting rapid deployment and drive highly profitable consumable sales For personal use only 1 Multiple letters from leading clinicians, front-line workers and the SNMMI have petitioned the USFDA for the
Slide 11: USA Economic Model
USA Economic Model USFDA Six Month Approval Review Concludes 29 September 2023 US EST For personal use only 1 Generator Placement Strategy designed to rapidly deploy the technology 2000 target nuclear medicine sites 200 generators at subassembly stage ready for final assembly 20 Generator plac
Slide 12: USA Timeline
USA Timeline Six Month Approval Review Completes 29 September 2023 US EST For personal use only 1 Completion of all required external testing – January 2023 Complete Response Letter Reply Submitted – 30 March 2023 2 The CRL contained over 145 supporting attachments, which comprehensively addre
Slide 13: Technegas: The Canadian Case Study
TECHNEGAS® Canada is Cyclopharm’s largest single country The Canadian Case Study market Market leader for diagnosing PE For personal use only 1 2 COVID – Patient volumes have recovered with further site conversion 3 Represents a strong indicator of USA acceptance 4 Xe-133 rapidly displaced by early
Slide 14: Hierarchy of Evidence
For personal use only Hierarchy of Evidence Technegas – Leveraging off the Highest Standard of Clinical Evidence in Traditional & Beyond PE Applications 14
Slide 15: What the Guidelines Say About Technegas
“ Using 99m-Tc-Technegas is according to clinical experience better than the best aerosols ” “ Technegas® facilitates interpretation, particularly in COPD” For personal use only “ For ventilation, 99m-Tc Technegas® is the best-aerosol particularly in patients with COPD ” WHAT THE “ Liquid aerosols a
Slide 16: Beyond PE: Exponential Global Growth Potential
For personal use only Beyond PE Exponential Global Growth Potential 16
Slide 17: Indication Expansion – The Importance, Urgency & Opportunity Beyond PE
Indication Expansion – The Importance, Urgency & Opportunity Beyond PE For personal use only 1 Lung Disease in 2019 accounted for 6 million deaths worldwide (12% of all deaths) 2 COPD and Lower Respiratory Infections and Lung Cancer will be the 3rd, 4th and 6th largest causes of death by 2030. “Over
Slide 18: Beyond PE applications of V/Q SPECT(/CT)
Beyond PE applications of V/Q SPECT(/CT) For personal use only Diagnosis and Preoperative Preoperative Planning radiation Advanced approach Use of alternate Diagnosis and follow-up of assessment of assessment of therapy to target to phenotyping isotopes to monitoring of Pulmonary homogeneous lung re
Slide 19: Three Distinct Value Horizons in the US & R.O.W.
THREE DISTINCT VALUE HORIZONS IN THE US & R.O.W. Exponential Growth Opportunity Over The Next Decade Pulmonary Embolism: Timeline USA PE Market Share US$ Revenue For personal use only potential p.a. Horizon 1 – Full displacement of existing 0- 5 years post 15% US$90m nuclear medicine tests for PE ap
Slide 20: CYC Business Case Summary
CYC Business Case Summary • Cyclopharm’s lead nuclear medicine product Technegas® is currently available in 64 countries 1 Cyclopharm Limited (CYC) is a leading diagnostic lung • • Over 4,700,000 patient procedures performed since first approved with 1,700 Technegas® generators sold globally Underly
Slide 21: Key Catalysts for the Next Years
KEY Catalysts for the Next 2 Years For personal use only 1 FDA approval for Technegas expected this week 2 First sales in US announce (shortly after approval) 3 Ongoing updates on Generators placed in US Clinical proof of concept & validation in new substantive ‘Beyond PE’ 4 respiratory indications
Slide 22: Thank You
For personal use only T H A N K YO U 22